Quick Answer
ClearPoint Neuro, Inc. reported Cash and Equivalents of $45.92 million for fiscal year 2025.
ClearPoint Neuro, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $45.92M | +128.4% |
| 2024 | $20.10M | -13.1% |
| 2023 | $23.14M | -16.2% |
| 2022 | $27.61M | -49.0% |
| 2021 | $54.11M | +169.2% |
| 2020 | $20.10M | +252.9% |
| 2019 | $5.70M | +83.7% |
| 2018 | $3.10M | -66.6% |
| 2017 | $9.29M | +180.2% |
| 2016 | $3.32M | -38.7% |
| 2015 | $5.41M | -41.5% |
| 2014 | $9.24M | +162.9% |
| 2013 | $3.52M | +117.1% |
| 2012 | $1.62M | +1013.6% |
| 2011 | $145.5K | -90.8% |
| 2010 | $1.58M | -38.6% |
| 2009 | $2.57M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $38.22M | +77.2% | -8.0% |
| June 30, 2025 | $41.54M | +26.5% | +235.4% |
| March 31, 2025 | $12.39M | -65.0% | -38.4% |
| December 31, 2024 | $20.10M | -13.1% | -6.8% |
| September 30, 2024 | $21.57M | -11.4% | -34.3% |
| June 30, 2024 | $32.84M | +24.1% | -7.1% |
| March 31, 2024 | $35.35M | +62.2% | +52.8% |
| December 31, 2023 | $23.14M | -16.2% | -4.9% |
- ClearPoint Neuro, Inc. showed an increase of +128.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, ClearPoint Neuro, Inc.’s cash and equivalents has grown by 1687.5% (from $2.57 million to $45.92 million).
- The most recent figure is from ClearPoint Neuro, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: